| Today’s Big NewsApr 7, 2025 |
|
Home to industry leaders like Amgen and AbbVie, Puerto Rico has over 70 years of pharmaceutical and biotech expertise. With a skilled workforce and world-class infrastructure, it remains a top destination for bioscience innovation. Find out how your company can thrive here. +(1)+(1).png)
|
|
| By James Waldron GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. |
|
|
|
By Nick Paul Taylor Duality Biologics has begun offering stock, wading into a market routed by Trump’s tariffs in pursuit of up to 1.56 billion Hong Kong dollars ($200 million) to fund its antibody-drug conjugate pipeline. Backers including BioNTech have committed around one-third of the targeted IPO haul. |
By James Waldron U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer antibody company.” |
Sponsored by Allucent Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how sponsors can align with FDA expectations and implement more precise dose-finding strategies. Watch the full interview with Alex MacDonald now! |
|
Understanding gender bias and diversity in donor pools is critical for lupus and autoimmune disease research. Using disease-state starting materials also offers unique opportunities… Read More > 
|
|
By Darren Incorvaia As scientists across the U.S. face increasing uncertainty due to funding freezes and mass layoffs at health agencies, German research institute BioMed X is stepping in to offer a lifeline. The institute has opened a matchmaking program to align threatened NIH grants with potential new funders from the pharmaceutical industry. |
By Nick Paul Taylor Lexeo Therapeutics has posted updated data in Friedreich ataxia patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a registrational trial. |
By Gabrielle Masson Sixteen state attorneys general are suing the Department of Health and Human Services and the National Institutes of Health over research grant terminations. It's the second major lawsuit challenging the funding cancellations filed against the agencies this week. |
By Darren Incorvaia Relay Therapeutics has laid off about 70 employees, the biotech's third round of cuts in less than a year. |
By Andrea Park Tapping into Henry Winkler’s status as a beloved Hollywood icon has majorly paid off for Apellis Pharmaceuticals, whose recent TV commercial for its geographic atrophy drug Syfovre starring the actor once known as Arthur Fonzarelli has been crowned the champion of this year’s Fierce Madness Drug Ad Tournament. |
By Darren Incorvaia Brown University has become the fifth university to be targeted by the Trump administration for funding cuts, according to reports, joining Ivy League peers Harvard University, Princeton University, Columbia University and the University of Pennsylvania. |
By Kevin Dunleavy Eli Lilly has sued Indianapolis-based spa Premier Weight Loss, claiming it buys tirzepatide autoinjector pens, cracks them open, breaking a sterile seal, and repackages them into lower unsterile doses, claiming the medicine is branded. |
By Zoey Becker Rhythm's Imcivree helped patients with obesity due to brain damage lose weight in a phase 3 study. With the trial win, the company is planning regulatory filings for what could be the first therapy approved in the rare disease population. |
By Fraiser Kansteiner On the heels of a recent cost-cutting drive that severed much of AmplifyBio’s R&D capacity, the Ohio-based contract manufacturing and research hybrid has hung up its hat for good. The company attributed the decision to a downturn in the market for early-stage development of cell and gene therapies, which it said stymied its ability to grow. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we dive into our special report ranking the top pharma R&D budgets for 2024. |
|
|---|
|
|
NashBio is transforming life sciences by making complex genomic and real-world data accessible for pharmaceutical R&D. Learn how their innovative Totem platform and groundbreaking Alliance for Genomic Discovery are accelerating research and improving outcomes. Sponsored by: NashBio |
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
